Silicone-based biophotonic compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-2017209484-A1
Application number	US-201515317316-A
Country	US
Kind code	A1
Filing date	Jun 9, 2015
Priority date	Jun 9, 2014
Publication date	Jul 27, 2017
Grant date	—

Abstract

The present disclosure provides silicone-based biophotonic compositions and methods useful in phototherapy. In particular, the silicone-based biophotonic compositions of the present disclosure include a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant. The silicone-based biophotonic compositions and the methods of the present disclosure are useful for promoting wound healing and scarring, as well as various other skin disorders.

First claim

1 . A biophotonic composition comprising a silicone phase and a surfactant phase, wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant.

2 . The biophotonic composition of claim 1 , wherein the surfactant phase is emulsified in the silicone phase.

3 . The biophotonic composition of claim 1 , wherein the surfactant comprises a block copolymer, wherein the block copolymer comprises at least one hydrophobic block and at least one hydrophilic block.

4 . (canceled)

5 . The biophotonic composition of claim 1 , wherein the surfactant phase comprises a surfactant which is thermogellable.

6 . (canceled)

7 . The biophotonic composition of claim 1 , wherein the surfactant comprises at least one sequence selected from the group consisting of polyethylene glycol-propylene glycol ((PEG)-(PPG)) , polyethylene glycol-polylactic acid (PEG)-(PLA), polyethyelene poly(lactic-c-glycolic acid) (PEG)-(PLGA), and polyethyelene glycol-polycaprolactone (PEG)-(PCL).

8 . The biophotonic composition of claim 7 , wherein the surfactant is a poloxamer.

9 - 12 . (canceled)

13 . The biophotonic composition of claim 1 , comprising from about 60 wt % to about 95 wt % silicone phase and from about 5 wt % to about 40 wt % surfactant phase, or about 80 wt % silicone phase, and about 20 wt % surfactant phase.

14 - 15 . (canceled)

16 . The biophotonic composition of claim 1 , wherein the surfactant phase further comprises a surfactant selected from the group consisting of cetyl trimethylammonium bromide (CTAB) and sodium dodecyl sulfate (SDS).

17 - 19 . (canceled)

20 . The biophotonic composition of claim 1 wherein the chromophore is a cationic chromophore selected from the group consisting of cyanine, acridine, pyronine Y, and their derivatives.

21 . (canceled)

22 . The biophotonic composition of claim 1 , wherein the chromophore is a xanthene dye selected from the group consisting of Eosin Y, Eosin B, Erythrosin B, Fluorescein, Rose Bengal, and Phloxin B.

23 . (canceled)

24 . The biophotonic composition of claim 1 , wherein the surfactant phase further comprises a stabilizer selected from the group consisting of gelatin, hydroxylethyl cellulose (HEC), carboxymethyl cellulose (CMC), and a thickening agent.

25 . (canceled)

26 . The biophotonic composition of claim 1 , wherein the composition is in the form of a gel, a membrane, or a film.

27 - 28 . (canceled)

29 . The biophotonic composition of claim 1 , wherein the composition is spreadable.

30 . A method for biophotonic skin treatment, comprising:
placing a composition over a target skin tissue, wherein the composition comprises a silicone phase and a surfactant phase, and wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant; and illuminating said composition with light having a wavelength that overlaps with an absorption spectrum of the at least one chromophore.

31 . (canceled)

32 . The method of claim 30 , wherein the skin treatment comprises treating a skin disorder selected from the group consisting of acne, eczema, psoriasis, and dermatitis.

33 . A method for promoting wound healing comprising:
placing a composition over a wound, wherein the composition comprises a silicone phase and a surfactant phase, and wherein the surfactant phase comprises at least one chromophore solubilized in a surfactant; and illuminating said composition with light having a wavelength that overlaps with an absorption spectrum of the at least one chromophore.

34 - 49 . (canceled)

50 . The method of claim 33 , wherein the method comprises treating or preventing scarring.

51 . The method of claim 30 , wherein the skin treatment comprises promoting skin rejuvenation.

52 . The method of claim 30 , wherein the composition is illuminated until the chromophore is at least partially photobleached.

53 . The biophotonic composition of claim 1 , wherein the silicone phase comprises a polydimethylsiloxane polymer (PDMS).

54 . The biophotonic composition of claim 53 , wherein the polydimethylsiloxane polymer is Sylgard 184.

55 . The biophotonic composition of claim 54 , wherein the content of the Sylgard 184 in the silicone phase is from about 5 wt % to about 100 wt %.

56 . The biophotonic composition of claim 53 , wherein the silicon phase further comprises Sylgard 527.

Assignees

• Klox Tech Inc

Inventors

• Piergallini Remigio
• Loupis Nikolaos
• Jaworska Joanna
• Devemy Emmanuelle
• Desrosiers Éric
• Chenite Abdellatif

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61P17/10

  Anti-acne agents · CPC title